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METHODS

Intracellular cytokine-producing CD4
+ and CD8 + T-cell monitoring was carried out in 30 liver transplant (LTr) and 31 kidney transplant (KTr) recipients from 2010 to 2012. Patients were assessed in our Department of Immunology at the Clinical University 'Hospital Virgen de la Arrixaca-IMIB' in Murcia, Spain for one year following transplantation. FACS Canto Ⅱ flow cytometer was employed to quantify the intracellular production of IL-17, IFNγ and IL-10 cytokines on stimulated CD4 + CD69
+ and CD8 + CD69 + T cells and BD FACS DIVA v.6 software was used to analysed the data. Statistical analysis was carried out using SPSS 22.0. T cells was shown to be the most significant recipient risk factor to develop opportunistic infection.
RESULTS
LTr
INTRODUCTION
Despite the continuous improvement in the clinical management of solid organ transplant recipients (SOTr), opportunistic infection (OI) remains one of the leading causes of morbidity and mortality in this population [1] . Although current immunosuppressive regimens aim to prevent allograft acute rejection (AR) [2] , clinicians still rely exclusively on therapeutic drug monitoring (TDM) of immunosuppression therapy (pharmacokinetics) to determine the immunological status of SOTr [3] . Indeed, the risk of an inadequate immunosuppression due to chronic exposure has been claimed to be one of the main reason of poor long-term outcomes [4, 5] ; hence there must be a balance to prevent not only AR but also reducing immunosuppression-related comorbidities, such as OI. Tailoring immunosuppressive regimens could potentially reduce the risk of life-threatening conditions, amongst other side effects, resulting in an improvement in the wellbeing of SOTr. Despite the aforementioned, TDM appears to be insufficient (intra-and inter-individual pharmacokinetic variability) in the provision of fulfilling information as to the real immunosuppressive status of SOTr [6] . In recent years new strategies, such as monitoring of cell-mediated immunity (CMI), have been seen to provide more accurate information with respect of the management of post-transplant SOTr. As such, CMI has been proposed as an alternative and reliable strategy in the search for predictive biomarkers of AR [7] [8] [9] [10] and OI [11] [12] [13] [14] amongst other clinical conditions.
The knowledge of T lymphocytes in host defense against infection has improved significantly over time. There is clear evidence that, upon pathogen derivedantigen contact, naïve T CD4 + (TH0) cells activate and differentiate into different functional subsets characterised by their cytokine secretion patterns (TH1, TH2, TH9, TH17, Tregs) [15] . Furthermore, when stimulated by microbial products through pattern recognition receptors (PRRs), antigen presenting cells (APCs) acquire the capacity to activate naïve T cells and differentiate into effector T cells that mediate adaptive immune responses. APCs stimulated with pathogens such as Bordetella pertussis, Klebsiella pneumoniae, and Mycobacterium tuberculosis produce a significant amount of IL-23, resulting in the development of TH17 cells, showing that this subset acts against both extracellular and intracellular infections [16, 17] . Evidence has shown that TH17 cells are also required for host defense against fungal infection [18] . The classically established TH1/TH2 paradigm yet describes the role of these two T lymphocyte subsets in host defense against infections. TH1 cells are essential in the elimination of intracellular pathogens such as Leishmania and Mycobacteria [19] , whereas TH2 secreted IL-10 cytokine cells has emerged as a key immunoregulator during infection with viruses, bacteria, fungi, protozoa, and helminths [20] . We therefore hypothesised, that CMI could be used to tackle T cell differentiation as a therapeutic target, providing thorough understanding of the adaptive immune response against pathogens after SOT. Hence, the aim of this uni-centre study was to prospectively monitor T helper lymphocyte cytokine responses against overall OI in a cohort of liver and kidney transplant recipients. As such, CMI could aid clinicians in the provision of better prophylaxis therapies, potentially reducing the occurrence of post-transplant OI.
MATERIALS AND METHODS
Study design
From 2010 to 2012, 61 consecutive adult patients; of whom 30 patients diagnosed with end-stage liver disease underwent LT and 31 patients diagnosed with end-stage renal failure underwent KT, alongside 16 healthy control (HC) volunteers were recruited from the Immunology Service of the Clinical University Hospital 'Virgen de la Arrixaca', Murcia (Spain) for a prospective uni-centre study. Peripheral venous blood samples were obtained from individual participants for laboratory testing at baseline as well as at several different posttransplantation time points (7 
Prophylaxis, immunosuppression and induction therapies
Cefuroxime (1500 mg/iv per 8 h) was administered to all methicillin-resistant Staphylococcus negative recipients, whereas Teicoplanin (200 mg/iv per 12 h) was given to patients positive for methicillin-resistant Staphylococcus. Oral Nystatin (5 cc/8 h) was also provided as Candida sp prophylaxis. Trimethoprimsulfamethoxazole (160/800 mg/iv per 24 h) was given, over six months, as Pneumocystis jiroveci pneumonia (PJP) prophylaxis. Oral Itraconazole (200 mg/24 h) was also given over three months to prevent Aspergillus sp. infection. Oral Pyrimethamine (25 mg/24 h) + folic acid was given as prophylaxis against Toxoplasma sp, with treatment extended up to six months in cases where serology was positive. In patients CMV seropositive, Ganciclovir (5 mg/kg per 12 h) or Valganciclovir (900 mg/kg per 12 h) were given as induction prophylaxis treatment. CMV prophylaxis induction with ivGanciclovir or oral-Valganciclovir for 2 wk followed up by oral-Valganciclovir for 3 mo. In those cases of a CMV seronegative recipient and CMV seropositive donor, the induction treatment was extended for 4 wk and maintained up to 6 mo. Post-transplantation CMV infections were treated with iv-Ganciclovir for 2 or 3 wk in both types of transplant, and oral-Valganciclovir was maintained for 3 mo. Finally, BK viral infection was treated by the administration of oral leflunomide (100 mg/24 h) over five days.
Initial immunosuppressive therapy consisted of oral Tacrolimus (TRL) 1 mg (6 mg/24 h) or oral Mycophenolic acid (MMF) 500 mg (1 g/24 h for KTr or 1.5 g/24 h for LTr) with Prednisone 20 mg/d with progressing tapering. The average drug level achieved for TRL was 2.6-17.3 ng/mL. The average drug level achieved for MMF was 0.40-4.15 µg/mL. The initial dose was modified in case of adverse side effects, such as diarrhea or leucopenia. In case of AR, the rescue therapy provided was based on the administration of steroid boluses (500-1000 mg methylprednisolone/24 h) for 3 d. In case of chronic rejection (CR), the rescue therapy provided was based on the administration of oral TRL (FK506; 0.1 mg/kg per 24 h).
Induction therapy was based on the administration of either thymoglobulin (1-1.5 mg iv/kg; Genzyme the intracellular cytokine production (IFNγ, IL-17 and IL-10) on peripheral CD4 + and CD8 + T lymphocytes. Table 1 List of type of opportunistic microorganisms that infected liver and kidney recipients during the post-transplant period n (%)
Opportunistic infection diagnosis
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infection by Clostridium difficile. Viral infection was determined using serological and molecular DNA-based methods. CMV infection was diagnosed by the presence of either IgM or IgG anti-CMV in symptomatic patients. CMV infection was assigned to either anti-CMV IgG antibody level ≥ 0.6 UI/mL or anti-CMV IgM antibody ≥ 30 UA/ml in symptomatic patients. Post-transplant active CMV and BK virus infections were confirmed using real-time polymerase chain reaction (qPCR) in plasma and/or urine samples. The presence of anti-EARLY IgG (≥ 1/10) and/or anti-VCA IgM (> 0.400 DO) in symptomatic patients was considered evidence of EBV infection. Similarly, only the presence of anti-HSV type 1 and 2 IgM (≥ 20 UI/mL) was considered evidence of active herpes virus infection.
Statistical analysis
Demographic data and results from our prospective follow-up study were collected and analysed in a unified database (SPSS 22.0, SPSS Inc., Chicago, IL, United States). Qualitative data are expressed as frequency and percentage. Quantitative data are shown as the mean ± SEM. Nonparametric Kolmogorov-Smirnov test was applied to identify whether the data followed a Gaussian distribution. Samples were adjusted to a nonparametric distribution. Nonparametric U Mann-Whitney test was applied to unpaired quantitative continuous variables, whereas nonparametric Wilcoxon test was applied to evaluate the relationship between paired quantitative continuous variables. Optimal biomarker cut-off points to discriminate between patients with and without OI were based on receiver operating characteristic (ROC) curves and calculated with the best Youden index (sensitivity + specificity-1) [21] . Discriminatory capacity was defined by the area under the curve (auROC) measure, with 0.7-0.8 deemed acceptable, 0.8-0.9 excellent and > 0.9 outstanding [22] . The predictive value for the model was assessed with χ 2 test. Survival curves for the first episode of OI were plotted using the Kaplan-Meier method, and differences between groups compared with the log-rank test. Recipient and donor factors were entered into univariate Cox model and those factors found to be significant at P < 0.25 level were subsequently entered into multivariate model, using a backward stepping procedure, to find the best model. In addition in this model AR, induction therapy and average drug dose were added as controlled variables. Results were expressed as hazard ratios (HRs) with 95%CIs. All statistical tests were two-tailed, with a P < 0.05 representing statistical significance.
RESULTS
Patient clinical and demographic characteristics
Overall, 60% of LTr and 61% of KTr developed at least one post-transplant OI event during the 1 st year posttransplantation. Generally, the infection pattern varied from bacterial, fungal and non-CMV infections following the first weeks post-transplantation to mainly CMV and non-CMV infections, such as HSV or HZV as previously described [15] , seen towards the end of the follow-up period. Recipient's clinical and demographic data found to be significant between infected-and non-infected-LTr and KTr are shown in Table 2 .
Percentage of TH1, TH2 and TH17 lymphocytes in endstage liver and renal failure patients Figure 3F ) T lymphocyte subsets experienced a significant early up-regulation, which remained constant during the post-transplantation period compared to their basal levels. These data are summarized in supplementary Table 1 . These data are shown in supplementary Table 2 .
Recipients with post-transplant opportunistic infection
Post-transplant cut-off values that accurately stratified liver and kidney transplant recipients at high risk of opportunistic infection
Following the stratification analysis, we wanted to find the potential capability of these T lymphocyte subsets as surrogate biomarkers capable of stratifying both LTr Table 3 .
The imbalance between the TH1 and TH2 response as the most significant risk factor associated with posttransplant opportunistic infection in liver and kidney transplant
We further examined the relationship between different recipient/donor factors and the occurrence of posttransplant OI in LTr and KTr. Following auROC curve analysis; univariate and multivariate Cox regression models were carried out. Results of the univariate and multivariate analysis of recipients and donor factors are shown in Table 4 . Several factors were shown to be associated with an increased risk of post-transplant OI in LTr as well as KTr. Amongst them, recipient gender and serum alkaline phosphatase (SALP) enzyme in LTr showed a trend (P = 0.067 and P = 0.078, respectively) to a worse post-transplant primary study point, whereas in KTr, recipient gender in conjunction with SALP, serum creatinine levels and dose of MMF, were significantly observed as independent risk factor of post-transplant OI episodes (P = 0.046, P = 0.016, P = 
DISCUSSION
This prospective study describes the usefulness of in vitro stimulation of whole peripheral blood to quantify the intracellular cytokine production capacity from two independent cohorts of patients (LTr and KTr) with orthotopic liver and kidney transplantation as predictive biomarkers for overall post-transplant OI. immune response in LTr was also found to have an impact to post-transplant infection. Importantly, we have demonstrated that post-transplant percentages for both pro-and anti-inflammatory cytokine-producing T lymphocytes to be the most significant factors determining the overall OI susceptibility. Pre-transplant levels of IFNγ, IL-17 and IL-10 producing T lymphocytes in patients with ELSF and ERSF were shown to be significantly different when compared to healthy individuals. Specifically, we found a significantly increased overall percentage of TH1, TH2 and TH17 populations in LTr, however in KTr TH1 and TH2 cells were observed no significant; nevertheless, there was a trend towards higher percentage in ESRF patients compared to healthy individuals. This data are in concordance with previous evidence showing an increased level of TH1 and TH17 cells in patients with ESRF [23] . Overall, the IFNγ-dependent immune response was shown to be significantly reduced in LTr and KTr during the follow-up period compared to basal levels. This reduced IFNγ production capacity was more substantial in liver than kidney recipients but nevertheless, in both cases a significant reduction in IFNγ production capacity was found within the highest OI occurrence in post-transplant period (1 st to 6 th month). On the other hand, IL-17 as well as IL-10-dependant responses increased gradually from day 1 up until one year after transplantation in both types of transplants and this increase was found significant compared to pre-transplant levels. Erol et al [24] 2017 investigated the intracellular IFNγ and IL-17 levels in a cohort of 50 KTr during 6 mo after transplantation. No significant difference was observed between preand post-transplant levels at any time point. However, Loverre et al [25] 2011 investigated a cohort of 72 KTr in which intracellular IFNγ (TH1), IL-4 (TH2) and IL-17 (TH17) production capacity was measured. Overall, they found a significant decrease in IFNγ expressing CD4 + T lymphocytes at 24 mo in patients with delayed graft function (DGF) compared to pre-transplant, whereas TH2 subset significantly increased after transplantation compared to baseline levels as measured by GATA3 protein expression in both patients with DGF as we all as acute tubular damage (ATD). Although our investigation did not compare post-transplant percentages of T lymphocytes with healthy individuals, our results shown concordance with the findings from P.J. van de Berg et al [26] 2012, in which they found a significantly decreased absolute number of CD4 + and CD8 + T cells in patients with stable graft function compared to healthy individuals at 6 mo, but more interestingly towards a differentiated and effector T-cell phenotype, specially observed in those CMV-seropositive recipients. OI has been found to be more frequent in the first six months after orthotopic liver [27] and kidney [28] transplantation when the immunosuppressant reaches maximum levels. NK-cells at month 1 post-transplantation [11] . Although, in our cohort of liver and kidney recipients the total count for both percentage and absolute number of peripheral lymphocytes was not statistically significant between both study groups, a trend was observed towards less count of total lymphocytes in patients with OI. The same study also used these T lymphocyte subpopulations as predictive biomarkers for OI, however they only took into consideration the quantitative side of the adaptive immune response against opportunistic pathogens. Thus, we believe that quantitative analysis, although rapid and affordable, could potentially miss beneficial information underlying the overall count of T CD4 + and CD8 + . Therefore, qualitative assays which provide functional information should also be performed to monitor transplant recipients. Consequently, intracellular cytokine quantification was carried out in this research as an estimation of the functional adaptive immune response against opportunistic pathogens. Our group had reported the usefulness of quantifying the intracellular cytokine production as a surrogate predictive marker of adverse event, such as acute cellular rejection, in LTr and KTr [9] . Moreover, the intracellular-staining method based on flow cytometry was previously used to monitor patients infected by intracellular [29] and extracellular [30] pathogens as well as to define immune-status in non-infected individuals. In spite of the methodology requiring specific equipment for its implementation and well-trained scientists in cell culture and flow cytometry, the majority of Histocompatibility laboratories already use similar approaches for their phenotypical and functional assays leading us to believe that such methodology should not have a significant cost impact. Where implementation can prove impossible, as in the case of many small laboratories, there would be the option of using a referral laboratory service, therefore reducing any financial impact.
Our data has demonstrated the accuracy of this s outcome in univariate analysis, this effect was not seen in multivariate analysis. In line with the findings in this research, the negative effect of the imbalance of cytokine-producing T lymphocytes in the overall posttransplant OI seen at pre-transplant in our LTr and KTr had yet been seen (data not shown).
In addition, we have also reported several recipient and donor factors that still remain critical determinants for morbidity outcome in solid transplant patients. Donor age has been associated with an increased risk of OI infection in both LT and KT [31, 32] , amongst other donor factors, such as CMV serostatus and deceased donor source. Recipient gender [33] and immunosuppressive therapy, especially MMF [32, 34] , as well as induction therapy [35] , have too been implicated in the susceptibility to some post-transplant OI. Our results confirm previous findings showing that donor age, recipient gender, immunosuppressive therapy with MMF and the administration of polyclonal antithymocyte globulin or basiliximab (anti-IL-2R or anti-CD25) should be taken into consideration as donor/recipient risk factors to posttransplant OI. On the other hand, we have also found serum levels of ALP and GGT in LTr and serum levels of ALP and creatinine in KTr to be associated with posttransplant OI; however, this data should be taken with caution as potential confounder may exist due to our small cohort of patients. Further investigation should be performed to elucidate these recipient factors as risks to post-transplant OI.
Analysis of our data has revealed several potential limitations. Likewise any uni-centre prospective study, the number of patients recruited to this purpose could have resulted as one limiting factor for the primary study outcome. Given that we have demonstrated significant associations in the basis of recipient/donor risk factors for post-transplant OI; these findings must be confirmed in larger (multi-center if possible) prospective study. Despite the limitations of the study.
In conclusion, our results add to the field of transplantation a validated, rapid and affordable CMI assay that provides basic functional information as to the monitoring of CD4 + and CD8 + T lymphocytes throughout the post-transplantation period. Based on these results, and those from recent studies, several post-transplant strategies could be proposed for the management of recipients. Particularly our study could be relevant in the setting of recipients showing an imbalance between the adaptive TH1 and TH2 immune response. Finally, our findings suggest that TH17 adaptive immune response, along with several recipient characteristics and donor age should be not consider in isolation but as a whole based on recipient features.
ARTICLE HIGHLIGHTS
Research background
Nowadays liver and kidney transplant are well-established therapeutic options for patients with end stage liver and kidney diseases. However, the administration of immunosuppressant is not exempt of side effects that ultimately could lead to worse transplant outcome.
Research motivation
Monitoring of adaptive immune response by flow cytometry provides means of further understanding on how T lymphocytes vary throughout the posttransplant period.
Research objectives
In this study, the authors aim to validate the intracellular cytokine production functional assay as means of cell-mediated immunity monitoring of posttransplant patients with opportunistic infection.
Research methods
A longitudinal study was carried out in two cohorts of transplant recipients where patients were prospectively monitored for one year post-transplantation.
Research results
LTr with OI had significantly lower % of CD8 
Research conclusions
The quantification of intracellular cytokine production by flow cytometry has been validated as a reliable functional assay that provides trustworthy information to a better management of transplanted patients. The occurrence of opportunistic infection was significantly correlated with an imbalance between TH1, TH2 and TH17 cells in both liver and kidney transplant recipients.
Research perspectives
Post-transplant administration of immunosuppressant as well as prophylaxis therapies could be adapted according to the levels of TH1, TH2 TH17 in an individual basis.
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